![ExpreS2ion Biotechnologies - Presentation of half-year 2024 report](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/b2521a8c-15e1-43b9-8557-0cfdcde9cb98.png)
ExpreS2ion Biotech Holding
0,879 SEK -4,77%HC Andersen Capital modtager betaling fra ExpreS2ion Biotech Holding for en Digital IR/Corporate Visibility abonnementsaftale. Læs mere her.
ExpreS2ion er en biotekvirksomhed med base i Danmark, men børsnoteret i Sverige. Virksomheden udvikler en portefølje af vacciner mod sygdomme som COVID-19, influenza og brystkræft gennem brugen af dets cellebaserede ekspressionssystem, ExpreS2, som er anerkendt for at håndtere protein udfordringer. ExpreS2ion har udviklet Expres2, som er en teknologiplatform til effektiv og hurtig ikke-klinisk udvikling og produktion af komplekse proteiner til nye vacciner og diagnostik. På nuværende tidspunkt er selskabets primære produkt corona-vaccinekandidaten, ABNCoV2 som er i fase 2, udviklet sammen med sin partner, AdaptVac, hvoraf ExpreS2ion ejer 34%. Vaccinekandidatens licensret tilhører Bavarian Nordic som har globale kommercialiseringsrettigheder og ansvar for yderligere klinisk udvikling af vaccinen.
Læs mereAnalyst
![Henrik Ekman Henrik Ekman](https://www.inderes.se/cdn-cgi/image/format=auto,width=128,height=128,quality=90,fit=cover/https://content.inderes.se/assets/6e03ef5d-f5bb-4113-a20b-1a7d036027c4.png)
![Claus Thestrup Claus Thestrup](https://www.inderes.se/cdn-cgi/image/format=auto,width=128,height=128,quality=90,fit=cover/https://content.inderes.se/assets/637ef734-dcbf-426c-bf91-0ac4a79aa71e.png)
Seneste videoer
Finanskalender
Større aktionærerKilde: Millistream Market Data AB
Ejer | Kapital | Stemmer |
---|---|---|
Saxo Bank A/S Client Assets | 9,2 % | 9,2 % |
BNY Mellon SA/NV for Jyske Ban | 5,6 % | 5,6 % |
Premium
This content is for our Premium customers only.
Forum opdateringer
![ExpreS2ion Biotechnologies - Presentation of half-year 2024 report](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/b2521a8c-15e1-43b9-8557-0cfdcde9cb98.png)
![Dagens aktienyheder 8/7-2024: Expres2ion Biotechnologies og Agillic](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=contain/https://content.inderes.se/assets/cff6bd5f-98ef-4d9b-bf2c-639cc0dfc0b5.png)
Dagens aktienyheder 8/7-2024: Expres2ion Biotechnologies og Agillic
ExpreS2ion Biotechnologies: ExpreS2ion resolves on a directed issue of units to guarantors in connection with the completed rights issue
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
![Dagens aktienyheder 4/7-2024: Penneo, Expres2ion Biotechnologies og RTX](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=contain/https://content.inderes.se/assets/1696de4a-b4de-4e9d-b58d-ad1abbb3dc5d.png)
Dagens aktienyheder 4/7-2024: Penneo, Expres2ion Biotechnologies og RTX
ExpreS2ion Biotechnologies: ExpreS2ion announces U.S. patent issue notification for glyco-engineered immunization antigens
![Dagens aktienyheder 02/07: Gubra, BioPorto A/S, Asetek og ExpreS2ion Biotechnologies](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=contain/https://content.inderes.se/assets/7f9f70e3-5d96-458f-a253-69d99d5b84ee.png)
Dagens aktienyheder 02/07: Gubra, BioPorto A/S, Asetek og ExpreS2ion Biotechnologies
ExpreS2ion Biotechnologies: ExpreS2ion announces final outcome of its rights issue
ExpreS2ion Biotechnologies: Rights issue subscription period ending 27 June 2024; subscription possible via form
ExpreS2ion Biotechnologies: ExpreS2ion announces poster presentation on the use of glycoengineered Drosophila S2 cells for production of highly immunogenic antigens at the ESACT meeting
![Dagens aktienyheder 24/6: ExpreS2ion Biotech, Scandinavian Medical Solutions og Vestas](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=contain/https://content.inderes.se/assets/02ce841d-d050-4d1c-a0c1-d0bf000984c1.png)
Dagens aktienyheder 24/6: ExpreS2ion Biotech, Scandinavian Medical Solutions og Vestas
ExpreS2ion Biotechnologies: Publication of clinical Phase Ib trial data for the adjuvanted RH5.1 blood-stage malaria vaccine
ExpreS2ion Biotechnologies: ExpreS2ion hosts informative webinar on 2024 Rights Issue and Highlights Key Updates on HER2+ Breast Cancer Vaccine
![ExpreS2ion Biotechnologies – Rights Issue 2024 (Recording)](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=contain/https://content.inderes.se/assets/ca70e718-91f4-4b0d-a261-f54bf0bef66f.png)
ExpreS2ion Biotechnologies – Rights Issue 2024 (Recording)
![ExpreS2ion Biotechnologies – Rights Issue 2024](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/ca70e718-91f4-4b0d-a261-f54bf0bef66f.png)
ExpreS2ion Biotechnologies – Rights Issue 2024
ExpreS2ion Biotechnologies: BioStock: Rights issue takes Expres2ion breast cancer vaccine to phase I
ExpreS2ion Biotechnologies: ExpreS2ion CEO to BioStock: "Compelling preclinical package gives us confidence"
ExpreS2ion Biotechnologies: The subscription period in ExpreS2ion's rights issue begins today
ExpreS2ion Biotechnologies: ExpreS2ion to present in upcoming investor and scientific events
![HCA Capital: Wrap up from 2024 Life Science seminar](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=contain/https://content.inderes.se/assets/ab49c0b1-56d0-4e1c-b729-6c79c89b7be2.png)
HCA Capital: Wrap up from 2024 Life Science seminar
![Dagens aktienyheder 6/6: GomSpace, ExpreS2ion og WindowMaster](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=contain/https://content.inderes.se/assets/2fe677ba-deba-48a7-832a-5461e4117566.png)